Literature DB >> 7068854

Long-lasting, specific immunologic unresponsiveness associated with cryptococcal meningitis.

D K Henderson, J E Bennett, M A Huber.   

Abstract

A sensitive radioimmunoassay and an antibody class-specific enzyme-linked immunosorbent assay were used to determine whether patients cured of cryptococcosis responded normally to immunization with cryptococcal capsular polysaccharide (CPS) and type III pneumococcal polysaccharide. 10 normal volunteers and 8 patients who had been cured of cryptococcal meningitis and who had been cured of cryptococcal meningitis and who had no serious underlying diseases were immunized with both antigens. Geometric mean titers to CPS measured by radioimmunoassay were 1:1 in both groups before vaccination, but were 1:3 in patients and 1:119 in controls following immunization (P less than 0.01, Student's t test). Analysis of the class-specific response to immunization with CPS found little anti-CPS IgG or IgA. Geometric mean postvaccination IgM titers were 1:31 in patients and 1:238 in controls (P less than 0.01). Responses to immunization with type III pneumococcal polysaccharide were similar in patients and controls, with IgA, IgM, and IgG mean titers of 1:1129, 1:369, and 1:158 in patients and 1:1504, 1:1039, and 1:163 in controls (P greater than 0.2 for each antibody class). Cured cryptococcal meningitis is often associated with prolonged specific immunologic unresponsiveness.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7068854      PMCID: PMC370184          DOI: 10.1172/jci110555

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  26 in total

1.  Airborne Cryptococcus neoformans: particles from pigeon excreta compatible with alveolar deposition.

Authors:  K E Powell; B A Dahl; R J Weeks; F E Tosh
Journal:  J Infect Dis       Date:  1972-04       Impact factor: 5.226

2.  Prognostic factors in cryptococcal meningitis. A study in 111 cases.

Authors:  R D Diamond; J E Bennett
Journal:  Ann Intern Med       Date:  1974-02       Impact factor: 25.391

3.  Serology of human cryptococcosis.

Authors:  D D Bindschadler; J E Bennett
Journal:  Ann Intern Med       Date:  1968-07       Impact factor: 25.391

4.  The wide spectrum of cryptococcal infections.

Authors:  J L Lewis; S Rabinovich
Journal:  Am J Med       Date:  1972-09       Impact factor: 4.965

5.  Serum immunoglobulin levels throughout the life-span of healthy man.

Authors:  C E Buckley; F C Dorsey
Journal:  Ann Intern Med       Date:  1971-11       Impact factor: 25.391

6.  Enzyme-linked immunosorbent assay (ELISA). Quantitative assay of immunoglobulin G.

Authors:  E Engvall; P Perlmann
Journal:  Immunochemistry       Date:  1971-09

7.  The effect of aging on human serum immunoglobulin concentrations.

Authors:  C E Buckley; F C Dorsey
Journal:  J Immunol       Date:  1970-10       Impact factor: 5.422

8.  Detection of circulating antibody in human cryptococcosis by means of a bentonite flocculation technique.

Authors:  H R Kimball; H F Hasenclever; S M Wolff
Journal:  Am Rev Respir Dis       Date:  1967-04

9.  Serologic tests in diagnosis and prognosis of cryptococcosis.

Authors:  M A Gordon; D K Vedder
Journal:  JAMA       Date:  1966-09-19       Impact factor: 56.272

10.  Immunological unresponsiveness induced by cryptococcal capsular polysaccharide assayed by the hemolytic plaque technique.

Authors:  J W Murphy; G C Cozad
Journal:  Infect Immun       Date:  1972-06       Impact factor: 3.441

View more
  23 in total

1.  The copper regulon of the human fungal pathogen Cryptococcus neoformans H99.

Authors:  Chen Ding; Jun Yin; Edgar Mauricio Medina Tovar; David A Fitzpatrick; Desmond G Higgins; Dennis J Thiele
Journal:  Mol Microbiol       Date:  2011-08-23       Impact factor: 3.501

Review 2.  Antibody immunity and invasive fungal infections.

Authors:  A Casadevall
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

3.  Effect of amphotericin B on capsule and cell size in Cryptococcus neoformans during murine infection.

Authors:  Oscar Zaragoza; Coralia Mihu; Arturo Casadevall; Joshua D Nosanchuk
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

4.  Genetic control of the humoral response to cryptococcal capsular polysaccharide in mice.

Authors:  F Dromer; P Yeni; J Charreire
Journal:  Immunogenetics       Date:  1988       Impact factor: 2.846

5.  Tolerance to cryptococcal polysaccharide in cured cryptococcosis patients: failure of antibody secretion in vitro.

Authors:  D K Henderson; V L Kan; J E Bennett
Journal:  Clin Exp Immunol       Date:  1986-09       Impact factor: 4.330

6.  Human natural killer cells do not inhibit growth of Cryptococcus neoformans in the absence of antibody.

Authors:  M F Miller; T G Mitchell; W J Storkus; J R Dawson
Journal:  Infect Immun       Date:  1990-03       Impact factor: 3.441

7.  Tissue localization of Cryptococcus neoformans glucuronoxylomannan in the presence and absence of specific antibody.

Authors:  D L Goldman; S C Lee; A Casadevall
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

8.  Immunohistochemical localization of capsular polysaccharide antigen in the central nervous system cells in cryptococcal meningoencephalitis.

Authors:  S C Lee; A Casadevall; D W Dickson
Journal:  Am J Pathol       Date:  1996-04       Impact factor: 4.307

9.  Production, characterization, and antibody specificity of a mouse monoclonal antibody reactive with Cryptococcus neoformans capsular polysaccharide.

Authors:  F Dromer; J Salamero; A Contrepois; C Carbon; P Yeni
Journal:  Infect Immun       Date:  1987-03       Impact factor: 3.441

10.  Protection of mice against experimental cryptococcosis by anti-Cryptococcus neoformans monoclonal antibody.

Authors:  F Dromer; J Charreire; A Contrepois; C Carbon; P Yeni
Journal:  Infect Immun       Date:  1987-03       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.